Poolbeg Pharma (LSE:POLB) has activated the first clinical trial site and started recruiting patients for its first-in-patient POLB 001 TOPICAL study. The single-arm, open-label trial will enrol approximately 30 patients with relapsed or refractory multiple myeloma who are being treated with the bispecific antibody teclistamab. The study is being conducted by specialist blood cancer research organisation Accelerating Clinical Trials Ltd and will assess POLB 001 as a potential preventative treatment for Cytokine Release Syndrome (CRS).
The company said the initiation of patient recruitment marks a significant operational milestone for its lead development programme. Due to the acute nature of Cytokine Release Syndrome, management expects a relatively rapid data readout from the study. Interest from investigators has been strong, reflecting the ongoing need for improved management of cancer immunotherapy-related CRS and the potential clinical value of a preventative treatment approach.
Should interim results prove positive, Poolbeg believes POLB 001 could strengthen its position within the cancer immunotherapy safety market, support future partnering opportunities and potentially expand access to advanced immunotherapies. By improving treatment tolerability, the therapy could help increase the number of patients eligible for these treatments and support wider adoption beyond specialist healthcare centres.
The company’s outlook continues to be influenced by weak financial fundamentals, including its pre-revenue status, ongoing losses, cash burn and shareholder equity erosion. However, progress towards clinical and regulatory execution, together with the prospect of interim data catalysts, provides a positive counterbalance. Technical indicators remain favourable, reflecting a strong upward trend in the shares, although overbought conditions may increase the risk of near-term volatility. Valuation metrics remain constrained by the absence of profitability and dividend payments.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biotechnology company focused on improving the safety and accessibility of cancer immunotherapies. Its lead candidate, POLB 001, is being developed to prevent Cytokine Release Syndrome, a potentially life-threatening side effect associated with certain cancer treatments. The company is also advancing an oral GLP-1 obesity therapy programme aimed at addressing a significant and rapidly expanding global market.
Leave a Reply